Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   41 News 


«12...4567891011121314...2627»
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed, Trial completion date, Trial primary completion date, Patient reported outcomes:  Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) (clinicaltrials.gov) -  Aug 31, 2023   
    P=N/A,  N=100, Active, not recruiting, 
    BIC/FTC/TAF Not yet recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Oct 2023 | Trial primary completion date: Jan 2022 --> Oct 2023
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment open:  Clinical Outcomes in HIV With Comorbidities (clinicaltrials.gov) -  Aug 30, 2023   
    P=N/A,  N=300, Recruiting, 
    Undiagnosed loss of HBcAb has no detrimental consequences on the response to BIC/FTC/TAF. Not yet recruiting --> Recruiting
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed:  PASO-DOBLE: DTG/3TC Vs. BIC/FTC/TAF Maintenance Therapy in People Living with HIV: (clinicaltrials.gov) -  Aug 25, 2023   
    P4,  N=555, Active, not recruiting, 
    Risk factors identified are: increased extent of Kaposi Recruiting --> Active, not recruiting
  • ||||||||||  doravirine/islatravir (MK-8591A) / Merck (MSD)
    Trial completion date, Trial primary completion date:  DOR/ISL in HIV-1 Antiretroviral Treatment-na (clinicaltrials.gov) -  Aug 18, 2023   
    P3,  N=500, Recruiting, 
    Trial primary completion date: Jul 2023 --> Jan 2025 Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Mar 2025 --> Oct 2025
  • ||||||||||  Journal:  Heart transplantation and human immunodeficiency virus-navigating drug-drug interactions: a case report. (Pubmed Central) -  Aug 16, 2023   
    The clinical outcome of this case supports the conclusion of previously published reports, summarized here within, demonstrating that HIV-1 positive status should not preclude HT in carefully selected individuals. Both addressing potential DDIs prior to HT and long-term monitoring for routine post-transplant complications and secondary and incidental malignancies are imperative.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Decay of human immunodeficiency virus (HIV) RNA in seminal plasma and rectal fluid in treatment-na (Pubmed Central) -  Aug 1, 2023   
    Comparable HIV-1 RNA decay in BP, SP, and RF was observed between DTG?+?3TC and BIC/F/TAF. As shown with triple-drug integrase inhibitor-based regimens, rapid HIV-1 RNA suppression in SP and RF is achieved with DTG?+?3TC, despite decay patterns differing from those of BP.
  • ||||||||||  Triumeq (dolutegravir/abacavir/lamivudine) / ViiV Healthcare, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Disseminated Histoplasmosis: A Gastrointestinal Manifestation (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3946;    
    It is important to note that HIV patients with HBV who stop antiretroviral agents that have activity against HBV (like Truvada, or Triumeq), are at higher risk of hep B reactivation, particularly HBV-related immune reconstitution. Figure: Patient's EGD which showed ulcerated mass with active bleeding in the 2nd portion of duodenum.
  • ||||||||||  Adcetris (brentuximab vedotin) / Seagen, Takeda, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Vanishing Bile Duct Syndrome: A Rare Cause of Hyperbilirubinemia (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_3042;    
    Several months prior to this presentation, he had been admitted with elevated liver enzymes, believed to be drug-induced liver injury (DILI) from recent initiation of Biktarvy, which resolved after discontinuation...The patient was initiated on immunotherapy with Brentuximab...Our report suggests that patients with HL and unexplained cholestasis should be considered for VBDS work up, including liver biopsy. Early recognition of this disease is crucial, as it may be reversed with chemotherapy, as in this case.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Uncommon Convergence: A Case Report of Coexisting CMV Esophagitis and Cryptosporidium Colitis in an HIV-Positive Patient (Exhibit Hall) -  Jul 29, 2023 - Abstract #ACG2023ACG_951;    
    Current symptoms persisted despite treatment with Bactrim, fluconazole, Valacyclovir, and Biktarvy, prompted the decision to undergo an Esophagogastroduodenoscopy (EGD), which revealed scattered esophagitis with a non-bleeding ulcer...Treatment was adjusted to include HAART, valganciclovir, and twice-daily PPI, leading to symptom improvement...Retroflexed views revealed no abnormalities. Image 'D': Rectal biopsies revealed colorectal mucosa with erosion and GMS-positive organisms within the crypt consistent with cryptosporidium parvum with PAS-D/ Mucicarmine and PAS-LG being positive for yeast forms and negative for CMV immunostaining.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial completion:  B/F/TAF Switch Study for HIV-HBV Coinfection (clinicaltrials.gov) -  Jul 20, 2023   
    P4,  N=28, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Trial primary completion date:  INSIGHT: INSTI's For The Management of HIV-associated TB (clinicaltrials.gov) -  Jul 13, 2023   
    P2b,  N=120, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Jul 2023 --> Jul 2024
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Atypical Dermoscopy Of Eyelid Moluscum Contagiosum () -  Jul 3, 2023 - Abstract #WCD2023WCD_5551;    
    KEY MESSAGE: Atypical varieties of MC may be large or non umbilicated without the classic dermoscopy pattern. They are frequent with immunosuppression and chronic unique lesions
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Enrollment closed:  Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide After Renal Transplant (clinicaltrials.gov) -  Jun 7, 2023   
    P4,  N=20, Active, not recruiting, 
    Despite a generally high genetic barrier to resistance, NRTI resistance-associated mutations may emerge during therapy with BIC/TAF/FTC in the setting of suboptimal adherence. Recruiting --> Active, not recruiting